Navigation Links
NSAIDs Won't Shield Against Skin Cancer
Date:2/15/2010

Researchers find anti-inflammatories show no effect on squamous cell carcinoma

MONDAY, Feb. 15 (HealthDay News) -- Countering prior indications that long-term use of NSAID painkillers might help reduce cancer risk, a new study suggests that these anti-inflammatory drugs offer no protection against a common skin cancer.

Previous research had suggested that routine use of NSAIDs -- including such over-the counter medications as Advil, Motrin, aspirin, Celebrex and Aleve (but not Tylenol) -- is associated with a reduced risk for the onset of colorectal, breast, prostate and lung cancer.

"Although there is some prior evidence, mostly laboratory-based, to suggest that NSAIDs can reduce the risk for the particular type of skin cancer called cutaneous squamous cell carcinoma, in our study, we didn't find that association," said the lead author, Dr. Maryam M. Asgari, an investigator in the research division at Kaiser Permanente Northern California (KPNC) in Oakland, Calif.

The study, which was supported by the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases and the U.S. National Cancer Institute, are published in the Feb. 15 online issue of the Archives of Dermatology.

To explore the potential connection between NSAIDs and skin cancer risk, Asgari and her colleagues administered questionnaires to a randomly selected pool of 415 patients between the ages of 43 and 85 who were diagnosed with skin cancer in 2004 and sought care at KPNC.

This group's self-reported NSAID-use history between 1994 and 2004 was stacked up against that of a group of 415 healthy patients. Both groups were similar in terms of age, race and gender. As well, records detailing pharmacy-dispensed NSAID patterns among all the patients were also examined for links to skin cancer incidence.

The authors noted that 61 percent of all the patients reported routine use of NSAIDs in the decade preceding the study. Specifically, 48 percent said they had used aspirin, 18 percent ibuprofen, 5 percent naproxen (ie, Aleve), and 4 percent nabumetone (Relafen).

But regardless of dosage used, type of medication taken, and/or whether NSAIDs were pharmacy-dispensed, the anti-inflammatory drugs were not found to be associated with a drop in skin cancer risk.

In fact, those patients who had taken NSAIDs for a relatively short period of time --anywhere from one to three years-- actually appeared to have a slightly increased risk for developing squamous cell carcinoma, the researchers said.

They concluded that NSAIDs did not seem to offer any protective effect with respect to skin cancer, and -- given the potential toxic side-effects of long-term NSAID use -- they suggested that patients at higher risk for skin cancer should be directed towards other safer, and perhaps more effective, interventions.

"We were surprised at the lack of NSAID protection," Asgari remarked. "Particularly when we saw an increased risk for skin cancer associated with the short-term use of NSAIDs. But actually that's not been unheard of, and I think there could be various explanations for this. Maybe people using NSAIDs short-term have other co-morbidities that make them more prone to having a weaker immune system and having poorer health. And also there are some forms of NSAIDs that do make you sun-sensitive, and more prone to getting DNA damage. That might be another explanation. But we were surprised."

However, Eric Jacobs, strategic director of pharmaco-epidemiology for the American Cancer Society, said Asgari's findings were not surprising.

"Results from this study are consistent with those of most previous studies," he said. "The best way to lower the risk of non-melanoma skin cancer, including squamous cell carcinoma, is to limit your exposure to strong sunlight -- for example by wearing a hat and using sunscreen -- and to avoid using tanning beds and sun lamps."

Dr. Alfred I. Neugut, head of cancer prevention and control at Columbia University's cancer center in New York City, also found the study's results unsurprising.

"Cutaneous squamous cell carcinoma is not your typical, run-of-the-mill cancer," noted Neugut, who is also co-director of cancer prevention at New York Presbyterian Hospital. "While it's one of the most common cancers -- maybe the most common -- it's not aggressive, not systemic, and related almost exclusively to sun exposure. So it is not really in the same category of cancers as, say, colorectal cancer or breast cancer."

Neugut added, "The fact that they found [NSAID use] has no effect is logical."

More information

For additional information on skin cancer risk, visit the American Cancer Society.



SOURCES: Maryam M. Asgari, M.D., M.P.H., investigator, division of research, Kaiser Permanente Northern California, Oakland, California; Eric Jacobs, PhD, strategic director of pharmaco-epidemiology, American Cancer Society, Atlanta; Alfred I. Neugut, M.D., PhD, head of cancer prevention and control, Herbert Irving Comprehensive Cancer Center, Columbia University, and co-director, cancer prevention, New York Presbyterian Hospital, New York City; Feb. 15, 2010, online Archives of Dermatology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Early Use of NSAIDs Might Prevent Alzheimers
2. NSAIDs Might Lower Breast Cancer Risk
3. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
4. NSAIDs No Better for Low Back Pain
5. NSAIDs Protect Against Parkinsons Disease
6. Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs, Says Harvard Mens Health Watch
7. Using coxibs and NSAIDs to treat osteoarthritis
8. Strict Blood Sugar Lowering Wont Ease Diabetes Heart Risk
9. Blue Cross and Blue Shield Association Expands Blue Distinction(R) Designation to Include Spine Surgery, Knee and Hip Replacement
10. Blue Cross and Blue Shield of Illinois Offers BlueCare Dental Plan
11. Blue Cross Blue Shield of Massachusetts Urges Members to Get Their Flu Shot
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol ... is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex ... in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement earlier this ... The former overall number one pick in the 2001 NFL Draft, to the Atlanta ... record for the most career rushing yards by a quarterback (6,109) and the most ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner ... Education Research Award. The award honors scholars exemplary in their capacity to communicate ... who has demonstrated the capacity to deepen the public’s understanding and appreciation of ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the undisputed ... Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more than 100 ... in the last 25 years. , Now, due to changes in the broadcast media ...
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class designers ... to bring their novel lifesaving device for the everyday use of parents worldwide. ... specially designed to read a child’s vital signs, and detect unusual symptoms or ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... 2017 Halo Labs announces the launch of ... system called the Horizon at PEGS 2017 in ... system analyzes sub visible particulate matter in biopharmaceutical samples ... as early as candidate selection and pre-formulation. ... research organization Elion Labs for system validation. ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
Breaking Medicine Technology: